VIDEO + B-ROLL: Emblem Corp. CEO Nick Dean welcomes Canada-wide adult-use cannabis legalization

TORONTO, Oct. 17, 2018 /CNW/ - Nick Dean, the chief executive officer of Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) ("Emblem" or the "Company") today welcomed the nationwide legalization of adult-use cannabis, a significant milestone that makes Canada the first-ever major industrialized economy to do so.

In a video, Dean heralded the formal inception of the legal recreational cannabis market and emphasized Emblem's continued commitment to medical patients post-October 17^th. Dean also spoke to:

Emblem Corp. staff tend to plants at the Company's facility in Paris, ON. (CNW Group/Emblem Corp.)

Emblem Corp. staff inspect plants at the Company's facility in Paris, ON. (CNW Group/Emblem Corp.)

Emblem Corp. CEO Nick Dean. (CNW Group/Emblem Corp.)

Nick Dean's video news release, part 1.

Nick Dean's video news release, part 2.

Nick Dean's video news release, part 3.

Emblem b-roll (video 4).

• Preparing for legalization (timestamp: video 1, 0:06)
• The future of the medical cannabis industry post-legalization (video 1, 0:58)
• Perspective on the taxation of medical cannabis (video 1, 1:49)
• International opportunities for the Canadian industry (video 2, 0:01)
• The importance of fighting impairment on our roads (video 2, 0:39)
• Emblem's unique business approach (video 2, 1:34)
• Product innovation (video 3, 0:01)
• The future of the cannabis industry in Canada (video 3, 1:05)

The video also contains footage from Emblem's licensed facility in Paris, Ontario, of the following:

• Cannabis plant inspection, cultivation and trimming (video 4, 0:01)
• Employees packaging dried flower product (video 4, 1:02)
• Cannabis flower examination and extraction equipment (video 4, 1:26)

For more information or to book interviews, please contact Morgan Cates, H+K Strategies, 416.413.4649, [email protected]

About Emblem

Emblem, through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR Emblem's state-of-the-art indoor cannabis cultivation facility and research and development laboratory is located in Paris, Ontario. Led by an experienced management team of healthcare executives, accomplished marketing professionals, and cannabis experts, Emblem is focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Emblem is also the parent company of GrowWise Health Limited, one of Canada's leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.

For more information, please visit http://emblemcorp.com/.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION 

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward-looking statements") within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "may", "will", "project", "should" or similar words, including negatives thereof, suggesting future outcomes. Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on information currently available to the Company, including data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which Emblem believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While Emblem is not aware of any misstatement regarding any industry or government data presented herein, the medical marijuana industry involves risks and uncertainties and is subject to change based on various factors.

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company's December 31, 2017 Management's Discussion and Analysis, which has been filed with the Canadian Securities Administrators and available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Emblem Corp.

For media inquiries, please contact: Morgan Cates, H+K Strategies, 416.413.4649, [email protected]; For investor inquiries, please contact: Ethan Karayannopoulos, Investor Relations, Emblem Corp., 647.748.9696, [email protected]; Alex Stojanovic, Chief Financial Officer, Emblem Corp., 416.923.1331, [email protected]